

CLAIMS

1. A method of micronizing (E)-4-[2-[2-[N-acetyl-N-(4-methoxybenzenesulfonyl)amino]phenyl]ethenyl]pyridine 1-oxide characterized in that the compound is pulverized with a mill of the open-circuit pulverizing type.

2. The micronizing method defined in Claim 1 wherein said mill of the open-circuit pulverizing type is either a high-speed rotary impact mill or a pneumatic mill.

3. The pulverizing method defined in Claim 1 or 2 characterized in that said compound (drug) is pulverized to a mean particle diameter of 1~25 μm with 50 μm and larger particles constituting a fraction of not more than 2%.

4. A crystalline (E)-4-[2-[2-[N-acetyl-N-(4-methoxybenzenesulfonyl)amino]phenyl]ethenyl]pyridine 1-oxide having a mean particle diameter of 1~25 μm with 50 μm and larger particles constituting a fraction of not more than 2%.

5. A pharmaceutical composition comprising the crystalline (E)-4-[2-[2-[N-acetyl-N-(4-methoxybenzenesulfonyl)amino]phenyl]ethenyl]pyridine 1-oxide defined in Claim 4 as an active

ingredient.

6. An anticancer drug comprising the crystalline (E)-4-[2-[2-[N-acetyl-N-(4-methoxybenzenesulfonyl)-amino]phenylethenyl]pyridine 1-oxide defined in Claim 4 as an active ingredient.